Detail Cantuman
Advanced SearchLars Sørensen
An interview with Lars Sørensen, chief executive officer (CEO) of the
pharmaceutical firm Novo Nordisk, is presented. When asked about
diversification, he states that he learned from the company's failed
attempt to enter the glucose monitoring sector that it is best to focus
on one area in which you can excel. Details on the firm's strategy of
selling both generic and differentiated products are presented.
Corporate social responsibility is also discussed.
Ketersediaan
Tidak ada salinan data
Informasi Detil
Judul Seri |
-
|
---|---|
No. Panggil |
-
|
Penerbit | Harvard Business School Publications : Boston., November 2015 |
Deskripsi Fisik |
p. 60 - 63
|
Bahasa | |
ISBN/ISSN |
0017-8012
|
Klasifikasi |
-
|
Tipe Isi |
-
|
Tipe Media |
-
|
---|---|
Tipe Pembawa |
-
|
Edisi |
-
|
Subyek |
-
|
Info Detil Spesifik |
-
|
Pernyataan Tanggungjawab |
-
|
Versi lain/terkait
Tidak tersedia versi lain